Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
Improvement in median overall survival from 5.8 years in 1995 to 2011 to not reached in 2009 to 2017.
Risk score identifies risk among patients with acute leukemia treated with anthracyclines before chemo
Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
AML survivors treated with blood or marrow transplantation have a greater risk of grade 3 or higher chronic health conditions, according to a survey that compared the long-term outcomes between survivors and their healthy siblings.